Reuters logo
BRIEF-Catalyst Biosciences announces emergence from key patent opposition period supporting marzeptacog alfa
March 30, 2017 / 9:42 PM / 8 months ago

BRIEF-Catalyst Biosciences announces emergence from key patent opposition period supporting marzeptacog alfa

March 30 (Reuters) - Catalyst Biosciences Inc

* Catalyst Biosciences announces emergence from key patent opposition period supporting marzeptacog alfa (activated), catalyst’s lead clinical program

* Catalyst Biosciences - Inc Research selected as CRO for Phase 2/3 efficacy clinical trial of Factor VIIA, marzeptacog alfa (activated); trial to commence in Q4 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below